A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA)

被引：30
|
作者：
De Jesus-Acosta, Ana
O'Dwyer, Peter J.
Ramanathan, Ramesh K.
Von Hoff, Daniel D.
Maitra, Anirban
Rasheed, Zeshaan
Zheng, Lei
Rajeshkumar, N. V.
Le, Dung T.
Hoering, Antje
Bolejack, Vanessa
Yabuuchi, Shinichi
Laheru, Daniel A.
机构：
[1] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[3] Scottsdale HealthCare, Scottsdale, AZ USA
[4] Scottsdale Healthcare TGen, Virginia G Piper Canc Ctr Clin Trials, Scottsdale, AZ USA
[5] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[6] Johns Hopkins Univ, Baltimore, MD USA
[7] Canc Res & Biostat, Seattle, WA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.257
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
257
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma
    De Jesus-Acosta, Ana
    Sugar, Elizabeth A.
    O'Dwyer, Peter J.
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    Rasheed, Zeshaan
    Zheng, Lei
    Begum, Asma
    Anders, Robert
    Maitra, Anirban
    McAllister, Florencia
    Rajeshkumar, N. V.
    Yabuuchi, Shinichi
    de Wilde, Roeland F.
    Batukbhai, Bhavina
    Sahin, Ismet
    Laheru, Daniel A.
    BRITISH JOURNAL OF CANCER, 2020, 122 (04) : 498 - 505
  • [2] Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma
    Ana De Jesus-Acosta
    Elizabeth A. Sugar
    Peter J. O’Dwyer
    Ramesh K. Ramanathan
    Daniel D. Von Hoff
    Zeshaan Rasheed
    Lei Zheng
    Asma Begum
    Robert Anders
    Anirban Maitra
    Florencia McAllister
    N. V. Rajeshkumar
    Shinichi Yabuuchi
    Roeland F. de Wilde
    Bhavina Batukbhai
    Ismet Sahin
    Daniel A. Laheru
    British Journal of Cancer, 2020, 122 : 498 - 505
  • [3] A phase II study of Chinese patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) for metastatic pancreatic cancer (MPC)
    Shen, Lin
    Yu, Xianjun
    Hao, Jihui
    Wang, Liwei
    Pan, Hongming
    Han, Guohong
    Xu, Jian-Ming
    Zhang, Yanqiao
    Yang, Shujun
    Chen, Jia
    Ying, Jieer
    Dai, Guanghai
    Li, Mingyu
    Begic, Damir
    Lu, Brian D.
    Xu, Ruihua
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [4] Gemcitabine (Gem) and nab-paclitaxel (nab-P) in patients (pts) with refractory advanced pancreatic cancer
    Palacio, Sofia
    Akunyili, Ikechukwu Immanuel
    Ernani, Vinicius
    Macintyre, Jessica
    Merchan, Jaime R.
    Pollack, Terri
    Reis, Isildinha
    Restrepo, Maria H.
    Lima, Caio Max S. Rocha
    Hosein, Peter Joel
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [5] Efficacy and safety of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) in Chinese patients (Pts) with metastatic adenocarcinoma of the pancreas (MPC): A phase II study
    Yu, X.
    Shen, L.
    Hao, J.
    Wang, L.
    Pan, H.
    Han, G.
    Xu, J.
    Zhang, Y.
    Yang, S.
    Ying, J.
    Li, M.
    Begic, D.
    Lu, B.
    Xu, R.
    ANNALS OF ONCOLOGY, 2015, 26 : 66 - 67
  • [6] Phase Ib study of WNT inhibitor ipafricept (IPA) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (mPC).
    Dotan, Efrat
    Cardin, Dana Backlund
    Lenz, Heinz-Josef
    Messersmith, Wells A.
    O'Neil, Bert
    Cohen, Steven J.
    Denlinger, Crystal S.
    Shahda, Safi
    Kapoun, Ann M.
    Brachmann, Rainer Karl
    Uttamsingh, Shailaja
    Weekes, Colin D.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [7] Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
    Weiss, Glen J.
    Blaydorn, Lisa
    Beck, Julia
    Bornemann-Kolatzki, Kirsten
    Urnovitz, Howard
    Schutz, Ekkhard
    Khemka, Vivek
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (01) : 96 - 102
  • [8] Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
    Glen J. Weiss
    Lisa Blaydorn
    Julia Beck
    Kirsten Bornemann-Kolatzki
    Howard Urnovitz
    Ekkhard Schütz
    Vivek Khemka
    Investigational New Drugs, 2018, 36 : 96 - 102
  • [9] Phase II study of pirfenidone combined with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer
    Guo, Guifang
    Li, Shengping
    Mao, Yize
    Yang, Qiuxia
    Yao, Zehui
    Wang, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] A PHASE I/II TRIAL OF WEEKLY NAB-PACLITAXEL (nab-P) plus GEMCITABINE(G) WITH METASTATIC PANCREATIC CANCER(MPC)
    Ikeda, Masafumi
    Ueno, Hideki
    Ueno, Makoto
    Mizuno, Nobumasa
    Ioka, Tatsuya
    Omuro, Yasushi
    Nakajima, Takako
    Furuse, Junji
    ANNALS OF ONCOLOGY, 2014, 25
12345